Brian M. Slomovitz, MD, discusses the some of the subcategories of endometrial cancer and how the make a difference for patients’ treatment.
Brian M. Slomovitz, MD, professor and chief in the Division of Gynecologic Oncology at the Sylvester Comprehensive Cancer, University of Miami Health System, discusses the some of the subcategories of endometrial cancer and how the make a difference for patients’ treatment.
Patients with endometrial cancer, more so than those with any other gynecological cancer, can fall into 1 of 4 subgroups as defined by the Cancer Genome Atlas (TCGA) Program. Slomovitz says that based on where a patients’ disease lies in terms of these subgroups, there are different outcomes as well as different treatment options. Patients with a mutated profile, high microsatellite instability, or mismatch repair deficiency are more amenable and more likely to respond to immunotherapy.
At the PER 11th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies, Slomovitz discussed biologic therapies and his study on mTOR inhibition in combination with hormonal therapy for these patients. Particularly in patients who were chemotherapy-naïve, he and his fellow investigators saw a high response rate and a longer progression-free survival. He thinks that physicians in this setting should take advantage of these response and survival rates by giving biological therapy sooner and holding the chemotherapy for later lines of treatment.